Phosphorylation, Signaling, and Cancer: Targets and Targeting by Marmiroli, Sandra et al.
Hindawi Publishing Corporation
BioMed Research International
Article ID 601543
Editorial
Phosphorylation, Signaling, and Cancer: Targets and Targeting
Sandra Marmiroli,1 Doriano Fabbro,2 Yoshihiko Miyata,3 Mariaelena Pierobon,4 andMaria
Ruzzene5
1Cellular Signaling Unit, Department of Surgery,Medicine, Dentistry andMorphology, University ofModena and Reggio Emilia, Largo
del Pozzo, 71-41100 Modena, Italy
2Piqur Therapeutics, Hochbergerstrasse 60C, 4057 Basel, Switzerland
3Department of Cell and Developmental Biology, Kyoto University, Kitashirakawa, Oiwake-cho, Sakyo-ku, Kyoto 606-8502, Japan
4Center for Applied Proteomics and Molecular Medicine, George Mason University, 10920 George Mason Circle, Manassas, VA 20110,
USA
5Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/b, 35131 Padova, Italy
Correspondence should be addressed to Sandra Marmiroli; sandra.marmiroli@unimore.it
Received 8 October 2015; Accepted 8 October 2015
Copyright © Sandra Marmiroli et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
After 60 years from the first report of an enzymatic phospho-
rylation of proteins, protein kinases are well-established key
signalingmolecules that impact allmajor biological processes
(reviewed in [1, 2]). Protein and lipid kinases fulfill essential
roles in many signaling pathways that regulate normal cell
functions [1–5]. Deregulation of kinase activities leads to
a variety of pathologies ranging from cancer to inflamma-
tory diseases, diabetes, infectious diseases, cardiovascular
disorders, and cell growth and survival [1, 2, 5–11]. A
much larger proportion of additional kinases are present
in parasites and bacterial, fungal, and viral genomes that
are susceptible to exploitation as drug targets [12]. Since
many human diseases result from overactivation of protein
and lipid kinases due to mutations and/or overexpression,
this enzyme class represents an important target for the
pharmaceutical industry [6]. Approximately one-third of all
protein targets under investigation in the pharmaceutical
industry are protein or lipid kinases and to date 33 small
molecular weight kinase inhibitors (SMWKIs) and a handful
of therapeutic antibodies have been approved for various
indications mainly in oncology and many more in various
stages of clinical and preclinical development [5]. Kinase
inhibitor drugs, which are in clinical trials, target all stages
of signal transduction from the receptor protein tyrosine
kinases that initiate intracellular signaling, through second-
messenger dependent lipid and protein kinases and protein
kinases that regulate the cell cycle [10, 13]. While treating
chronic phase CML (an almost monogenic disease) with
imatinib has been very successful, the treatment of more
advanced cancers with kinase inhibitors has proven more
difficult due to the heterogeneity of these cancer types as well
as due to kinase inhibitor resistance resulting from selection
formutant alleles and/or upregulation of alternative signaling
pathways [5, 10].
In addition, powerful broad-scale protein pathway acti-
vation mapping and phosphoprofiling of protein kinases and
of their specific substrates are contributing to driving the new
concept of precisionmedicine [14–16]. Notable advances have
beenmade in the rational design of small-molecule inhibitors
that target unique kinase conformational forms and binding
sites and have specific kinase selectivity profiles [5, 17–19].
This special issue provides a selection of original articles
focused on kinase targets and therapeutic approaches based
on kinase targeting in different cell systems and pathological
conditions.
Resistance is a major drawback of conventional
chemotherapy. The understanding of the mechanisms
by which some cancer cells are resistant to ATRA (all-trans-
retinoic acid) is crucial in anticancer drug development
and requires detailed knowledge of the signaling pathways
affected by ATRA. In the paper by R. S. Q. Barceinas et al.,
the authors show that, in lung cancer cells, ERK pathway
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activation is involved in the transcription-independent
effects of ATRA.They also found that ERK targeting restores
the beneficial effects of ATRA, suggesting that combined
treatments with ATRA and ERK inhibitors could represent a
promising strategy in lung cancer therapy.
Targeting of pathways aberrantly activated in cancer is a
very powerful approach that has provided promising results,
with several drugs already in clinical trials for a number of
diseases.The work byM. Civallero et al. provides an excellent
example of preclinical testing and comparison of the cyto-
toxicity of two different kinase inhibitors, namely, the pan-
PI3K inhibitor BKM120 and the dual PI3K/mTOR inhibitor
BEZ235, on mantle, follicular, and T-cell lymphomas, in
which the PI3K pathway is known to be hyperactive. They
demonstrated that BKM120 and BEZ235 show high effective-
ness against lymphoma cells in vitro both asmonotherapy and
in combination. Because the outcome of lymphoma patients
is still very poor, in spite of the great advances following
the introduction of monoclonal antibodies based therapy of
lymphoma, the results of this work open a new therapeutic
window for these malignancies.
Along the same lines, the original work by C. Frasson et
al. shows the pivotal role played by the PI3K/Akt pathway
in promoting survival of primary medulloblastoma cells, the
most frequent primitive neuroectodermal tumor in children,
with a dismal prognosis in more than one-third of patients.
In particular, the authors demonstrate that specific targeting
PI3K impairsmedulloblastoma primary cells growth and sur-
vival through the activation of the mitochondrial cell death
program. Remarkably, PI3K signaling suppression seems to
selectively hit the cancer stem cell population, sparing the
most differentiated cellular counterpart. Since cancer stem
cells have been reported to be one of the driving forces of
tumor progression and resistance to therapy, these results
may guide the development of new combinatorial therapeutic
strategies aimed at impairing the survival machinery of both
cancer stem cells and tumor bulk cells.
The acidophilic kinase CK2 has been shown to play
prominent roles in carcinogenesis. In the paper by C. Girardi
et al., the authors analyze two inhibitors of CK2, namely, TDB
and CX-4945. In particular, they compare their efficacy in
terms of persistence of inhibitory effects after their removal.
They find a superiority of TDB compared to CX-4945, and
they conclude that this property is an added value to be
considered when planning new therapies based on CK2
targeting.
Inhibition of CK2 is also the focus of the paper by G.
Cozza et al., where the authors analyze the properties of
quinalizarin, extending its selectivity profile to 140 protein
kinases. Consistent with in silico and in vitro analyses, they
conclude that quinalizarin not only is one of the most selec-
tive inhibitors of CK2 but is also able to discriminate between
the isolated CK2 catalytic subunit and CK2 holoenzyme.
A different aspect of the Akt kinase functions has been
explored by G. Vallejo-Flores and coauthors. Based on the
observation that H. pylori infection is the most important
environmental risk to developing gastric cancer, mainly,
through its virulence factor CagA, they evaluated the capacity
of H. pylori CagA positive and negative strains to alter
nontransformed glandular acini formation. They found that
the Akt and BIM signaling pathway is activated in CagA
positive strains and might thus contribute to its oncogenic
activity through evasion of anoikis.
Overall, this special issue highlights the contribution of
targeting signaling pathways in tumorigenesis and describes
which compounds are more promising in the future for
chemoprevention and anticancer therapy on the basis of their
ability to inhibit specific signaling targets.
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